Alkayyal Almohanad A, Darwish Manar, Ajina Reham, Alabbas Saleh Y, Alotaibi Mohammed A, Alsofyani Abeer, Bokhamseen Maha, Hakami Maumonah, Albaradie Omar A, Moglan Abdulaziz M, Hala Sharif, Alsahafi Abdullah Faisal, Zakri Samer, Almuzaini Adnan, Alsharari Khamis, Kaboha Feras, Taher Mustafa Y, Zein Haggag S, Alroqi Fayhan, Mahmoud Ahmad Bakur
Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Front Bioeng Biotechnol. 2023 Jul 17;11:1150892. doi: 10.3389/fbioe.2023.1150892. eCollection 2023.
The coronavirus disease 2019 (COVID-19) pandemic imposes an urgent and continued need for the development of safe and cost-effective vaccines to induce preventive responses for limiting major outbreaks around the world. To combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we repurposed the VSV∆51M oncolytic virus platform to express the spike receptor-binding domain (RBD) antigen. In this study, we report the development and characterization of the VSV∆51M-RBD vaccine. Our findings demonstrate successful expression of the RBD gene by the VSV∆51M-RBD virus, inducing anti-RBD responses without attenuating the virus. Moreover, the VSV∆51M-RBD vaccine exhibited safety, immunogenicity, and the potential to serve as a safe and effective alternative or complementary platform to current COVID-19 vaccines.
2019年冠状病毒病（COVID-19）大流行迫切且持续需要研发安全且具成本效益的疫苗，以引发预防反应来限制全球范围内的重大疫情爆发。为抗击严重急性呼吸综合征冠状病毒2（SARS-CoV-2），我们重新利用VSV∆51M溶瘤病毒平台来表达刺突受体结合域（RBD）抗原。在本研究中，我们报告了VSV∆51M-RBD疫苗的研发与特性。我们的研究结果表明，VSV∆51M-RBD病毒成功表达了RBD基因，诱导了抗RBD反应且未减弱病毒活性。此外，VSV∆51M-RBD疫苗展现出安全性、免疫原性，并有潜力作为当前COVID-19疫苗的安全有效替代或补充平台。
